about
Transplant-associated thrombotic microangiopathy: opening Pandora's box.Diffusion-assisted high-resolution direct femtosecond laser writing.Hematopoietic cell transplantation and emerging viral infections.Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT.Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advancedA prospective study of incidence, clinical and quality of life consequences of oral mucositis post palifermin prophylaxis in patients undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation.Thyroid dysfunction in adult long-term survivors after hemapoeitic stem-cell transplantation (HSCT).The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: a retrospective analysis.Autologous HSCT for systemic sclerosis.Molecular evidence for repertoire skewing of T large granular lymphocyte proliferation after allogeneic hematopoietic SCT: report of two cases.Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.Function of the hypothalamic-pituitary-gonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases.Candida is an emerging pathogen beyond the neutropenic period of allogeneic hematopoietic cell transplantation.The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes.Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases.Outbreak of novel influenza A (H1N1) in an adult haematology department and haematopoietic cell transplantation unit: clinical presentation and outcomeUnraveling the Genetics of Transplant-Associated Thrombotic Microangiopathy: Lessons to be LearnedSurvival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell TransplanSilent T-cell lymphoma of γδ T-cell origin initially presented as panniculitisGVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantationExtracorporeal photopheresis in the treatment of chronic graft-versus-host disease. The Hellenic experience: A study by the Hellenic association of hematologyOutcomes of Hodgkin’s Lymphoma Patients with Relapse or Progression following Autologous Hematopoietic Cell TransplantationAutologous haematopoietic stem cell transplantation in a patient with refractory Crohn's diseaseLong-term results of stem cell transplantation for MS: A single-center experienceVeno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantationBEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphomaReader response: Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic strokeFavorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center studyErratum: Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?low body mass index is an independent risk factor for transplant-associated microangiopathy following total-body irradiation-based conditioning regimensGVL effect in plasmacytoid DC leukemia/lymphomaReversible painful oral mucosal hyperpigmentation following palifermin administrationDonor EBV at the time of hematopoietic cell transplantation: Is it time to adopt molecular assays?Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative studyPositive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysisTransplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantationAutologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents
P50
Q30235311-ACD6714C-9D0D-4BA2-AE59-C3F0ED866CA0Q34156069-D5CF3F26-AC3E-4242-AF25-587975A648B6Q37678301-21DD846F-F64E-4FF7-9770-8D6E6FD4AD15Q38951604-E1742E5D-3BB3-4CFF-BB34-C53088357711Q38955398-FE50DEDD-7630-47F4-9C08-BC57929F4473Q40237552-20728941-8AA9-4A61-8BE3-1F7567289B1FQ41437866-E8537A81-46FD-4C0E-861C-01FA3B4CBE8CQ41614364-C11777D1-44BE-4B1B-B18F-7F91A9F4A0FEQ42483467-2CDF116F-105B-4A93-8ADB-6D838041950AQ43153439-A017FBD1-FC2B-4D1B-86E6-ABBBCF01EDE2Q43564139-E6A71AE9-76EE-4A89-A41D-2BFC2DB81B3EQ44944695-99B733AF-0FCE-403E-8321-7D64FE17EF4AQ45038899-59B0ADF7-BCA1-439F-921D-F246CAA1CA30Q46622312-C71729AE-ACF5-4DD2-8C8E-BA2AB52D727FQ48209498-9B21537D-0BBD-4B45-8C74-FEBEB5E5EB3FQ50527332-E93C4022-D5CD-4F08-9339-0CCFAD211A4DQ53090413-9619A33A-33EA-4FA6-80BE-2D436BF7B61EQ54306708-B695089E-0661-46D3-AFF3-BE2442BA8C37Q57098094-832E49C1-B59A-4F0B-AA48-5BBAE582EE32Q58041501-E7992E82-4738-424F-BDFB-F82CF83FE7CAQ58041511-90F2662E-4314-49D7-879C-1D8BC9965C85Q58041530-DB9D74E2-0C31-4873-9D77-B752E1CB9F64Q58041555-0D761A60-56C8-47B5-9A87-E3F35B1B996DQ58041577-3A907051-8866-46C2-8E56-9D2316F682EEQ58041582-DA5976A3-5032-4275-9BEF-CCED4291EC03Q58041597-73E51CFC-3BB3-4F5B-8D62-1A1D9A3B5ED5Q58041599-8667B30E-7702-4E2D-9AA8-63A44908544CQ58041637-45F1E054-A920-4711-92EB-3B0AE01743A4Q58576852-C0DA6455-C737-4CE9-8AEF-DAD7B23A0A09Q58608246-2E37AD5A-2C22-412A-9A32-DBA184DE74F4Q58610776-3335E96C-B0CD-4028-B113-BAF19BCFF83EQ61163151-DAE31712-B493-4EDD-AD65-8195B86C3737Q81817471-9D34C3E0-8A32-4473-9EA2-E7E0D629381DQ84626317-952A07D4-8ADD-4E5D-A93A-0D077F6E0942Q85230799-C08F2DED-BCD2-48CC-8FD5-2D652BE53DC7Q87884213-24CC1E62-D95F-409E-8709-720DEAA9E7ECQ88992920-DD88C622-C91A-4D57-AF33-7B40DB4E1967Q89038052-3B7996B3-228C-422F-B3D3-D700FC8DAE10Q90771508-4053586A-1629-4BF0-B1A8-6559CAA97514Q92155614-07D7A89A-A920-456D-8E0D-DF69F2FFD826
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Ioanna Sakellari
@ast
Ioanna Sakellari
@en
Ioanna Sakellari
@es
Ioanna Sakellari
@nl
type
label
Ioanna Sakellari
@ast
Ioanna Sakellari
@en
Ioanna Sakellari
@es
Ioanna Sakellari
@nl
prefLabel
Ioanna Sakellari
@ast
Ioanna Sakellari
@en
Ioanna Sakellari
@es
Ioanna Sakellari
@nl
P31
P496
0000-0003-4325-8856